Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?
Open Access
- 22 August 2019
- journal article
- review article
- Published by Springer Science and Business Media LLC in Journal of Experimental & Clinical Cancer Research
- Vol. 38 (1), 1-22
- https://doi.org/10.1186/s13046-019-1362-1
Abstract
Survivin (also named BIRC5) is a well-known cancer therapeutic target. Since its discovery more than two decades ago, the use of survivin as a target for cancer therapeutics has remained a central goal of survivin studies in the cancer field. Many studies have provided intriguing insight into survivin’s functional role in cancers, thus providing promise for survivin as a cancer therapeutic target. Despite this, moving survivin-targeting agents into and through the clinic remains a challenge. In order to address this challenge, we may need to rethink current strategies in order to develop a new mindset for targeting survivin. In this Review, we will first summarize the current survivin mechanistic studies, and then review the status of survivin cancer therapeutics, which is classified into five categories: (i) survivin-partner protein interaction inhibitors, (ii) survivin homodimerization inhibitors, (iii) survivin gene transcription inhibitors, (iv) survivin mRNA inhibitors and (v) survivin immunotherapy. We will then provide our opinions on cancer therapeutics using survivin as a target, with the goal of stimulating discussion that might facilitate translational research for discovering improved strategies and/or more effective anticancer agents that target survivin for cancer therapy.Keywords
Funding Information
- NIH/NCI (R44CA176937, R43CA221389)
This publication has 171 references indexed in Scilit:
- Interleukin Enhancer-binding Factor 3/NF110 Is a Target of YM155, a Suppressant of SurvivinMolecular & Cellular Proteomics, 2012
- Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanomaCancer Immunology, Immunotherapy, 2012
- Disabling the mitotic spindle and tumor growth by targeting a cavity-induced allosteric site of survivinOncogene, 2011
- Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose StudyClinical Cancer Research, 2010
- Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugsBritish Journal of Cancer, 2010
- Activation of AMP-activated Protein Kinase α1 Alleviates Endothelial Cell Apoptosis by Increasing the Expression of Anti-apoptotic Proteins Bcl-2 and SurvivinJournal of Biological Chemistry, 2010
- A Survivin-Ran Complex Regulates Spindle Formation in Tumor CellsMolecular and Cellular Biology, 2008
- Reduced Expression of DNA Topoisomerase I in SF295 Human Glioblastoma Cells Selected for Resistance to Homocamptothecin and DiflomotecanMolecular Pharmacology, 2007
- P-Glycoprotein and Breast Cancer Resistance Protein: Two Dominant Transporters Working Together in Limiting the Brain Penetration of TopotecanClinical Cancer Research, 2007
- Molecular mechanism of upregulation of survivin transcription by the AT-rich DNA-binding ligand, Hoechst33342: evidence for survivin involvement in drug resistanceNucleic Acids Research, 2007